Browse our comprehensive collection of market intelligence reports.
The global diagnostic biomarkers market comprises molecular, biochemical, cellular, and histopathological indicators that support disease detection, patient stratification, therapeutic selection, disease monitoring, and treatment response assessment across multiple clinical specialties. The market is functioning as a critical component of precision medicine because biomarkers enable clinicians to identify disease-specific biological changes before clinical symptoms become fully established.</
The Global Colorectal Cancer Companion Diagnostics Market supports treatment selection by identifying molecular biomarkers that predict therapeutic response and resistance in patients with colorectal cancer. The market encompasses molecular assays, immunohistochemistry, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based tests, and bioinformatics solutions that guide precision oncology decisions. Demand is shifting from single-gene testing toward comprehensive biomarker pr
The global breast cancer companion diagnostics market supports precision oncology by identifying predictive biomarkers that guide targeted treatment selection and therapeutic monitoring. The market function is shifting from single-gene testing toward comprehensive molecular profiling because oncologists increasingly require biomarker-driven evidence before initiating high-value targeted therapies. Growing adoption of next-generation sequencing (NGS), multiplex molecular assays, and liquid bio
The global oncology companion diagnostics market supports precision oncology by identifying patients who are most likely to benefit from targeted therapies based on specific molecular and genetic biomarkers. Demand is shifting from single-gene testing toward comprehensive genomic profiling because oncology drug pipelines are expanding across multiple biomarker-defined patient populations. This transition places companion diagnostics at the center of therapeutic decision-making and strengthens
The global immunotherapy companion diagnostics market supports precision oncology by identifying patients who are most likely to benefit from immune checkpoint inhibitors and other immuno-oncology therapies. Companion diagnostics integrate molecular and protein biomarker assessment with therapeutic decision-making, enabling clinicians to improve treatment selection while reducing exposure to ineffective therapies. Demand is shifting toward multiplex biomarker profiling because single-marker t
The global tuberculosis (TB) diagnostics market supports the timely identification of Mycobacterium tuberculosis infection across active disease, latent infection, drug-resistant tuberculosis, and treatment monitoring. Demand is shifting from conventional microscopy and culture toward rapid molecular diagnostics because national tuberculosis elimination programs require earlier case detection, improved drug-resistance identification, and decentralized testing. This transition is incr
The global lung cancer companion diagnostics market supports precision oncology by identifying predictive biomarkers that determine patient eligibility for targeted therapies and immunotherapies. The market function centers on linking molecular test results with regulatory-approved therapeutic decisions, enabling clinicians to select treatments based on tumor-specific genomic alterations rather than histological classification alone. Growing integration of next-generation sequencing (NGS), po
The global HIV diagnostics market supports early disease identification, treatment monitoring, blood safety screening, and public health surveillance across healthcare systems. Demand is shifting from centralized laboratory testing toward decentralized diagnostic platforms because healthcare providers are prioritizing earlier diagnosis, rapid clinical decision-making, and expanded testing coverage among high-risk and underserved populations. This transition is increasing the adoption of rapid
The global hepatitis diagnostics market supports early disease identification, treatment selection, therapeutic monitoring, and population-level screening across viral hepatitis infections. Demand is shifting toward molecular diagnostics and automated laboratory platforms because healthcare systems are prioritizing earlier detection to reduce long-term complications such as cirrhosis and hepatocellular carcinoma. This transition increases the importance of high-sensitivity assays capable of i
The global companion diagnostics market is becoming an integral component of precision medicine because therapeutic decision-making increasingly depends on validated biomarker identification rather than disease classification alone. Drug developers, diagnostic manufacturers, healthcare providers, and regulatory agencies are expanding coordinated development models that align diagnostic assays with targeted therapeutics throughout clinical development. This integration supports patient stratif
The lung cancer diagnostics market is becoming increasingly centered on precision medicine as clinical decision-making depends on biomarker-driven patient stratification rather than histological classification alone. Diagnostic demand is expanding beyond initial disease confirmation because clinicians are requiring comprehensive molecular characterization to guide targeted therapies, immunotherapies, and longitudinal disease monitoring. This transition places molecular diagnostics, liquid bio
The global portable PCR market supports decentralized molecular diagnostics by enabling rapid nucleic acid amplification outside conventional laboratory settings. The market is serving healthcare providers, public health agencies, veterinary laboratories, food safety authorities, environmental monitoring organizations, and research institutions that require accurate molecular testing at the point of need. Demand is shifting from centralized laboratory workflows toward field-deployable diagnos